Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease

OBJECTIVES: Levodopa-carbidopa intestinal gel (LCIG) was developed to reduce motor complications in Parkinson’s disease (PD) caused by pulsatile levodopa plasma concentrations following oral levodopa administration. Dyskinesia and ‘wearing off’ symptoms can vary between Asian and Caucasian patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Murata, Miho, Mihara, Masahito, Hasegawa, Kazuko, Jeon, Beomseok, Tsai, Chon-Haw, Nishikawa, Noriko, Oeda, Tomoko, Yokoyama, Masayuki, Robieson, Weining Z., Chatamra, Krai, Facheris, Maurizio F., Benesh, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833238/
https://www.ncbi.nlm.nih.gov/pubmed/29511383
http://dx.doi.org/10.1177/1756286418759315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833238/
https://www.ncbi.nlm.nih.gov/pubmed/29511383
http://dx.doi.org/10.1177/1756286418759315

Ejemplares similares